Navigation Links
FDLI's Food and Drug Policy Forum Examines European GMO Rules
Date:1/25/2011

WASHINGTON, Jan. 25, 2011 /PRNewswire-USNewswire/ -- The second issue of FDLI's Food and Drug Policy Forum (Volume 1, Number 2), to be published January 26, 2011, focuses on the increasingly important issue of genetically modified organisms (GMOs).

In the article published on the Food and Drug Law Institute's website (www.fdli.org), Ross H. Pifer, Director, and Richard J. Lupinsky, Jr., Research Fellow at the Agricultural Law Resource and Reference Center at Penn State University's Dickinson School of Law, make recommendations on this emerging international food and drug issue: "Should the European Union Proceed with the Implementation of New GMO Rules?"

Pifer and Lupinsky conclude that new GMO rules in the European Union need additional clarity to create a proper framework for the approval of genetically modified products, explaining that "stakeholders on all sides believe that the proposal actually will increase legal uncertainty and create more chaos surrounding both the decision-making process and labeling standards." The authors specifically recommend that the European Commission modify the major standard expressed in proposed Article 26b(a), a European Union Member States' Directive, to better explain the specific bases upon which Member States can restrict or prohibit cultivation of particular GMOs, integrate and harmonize the content of Article 26b with the Safeguard Clause, and maintain uniform standards of labeling for GMOs.

FDLI's Food and Drug Policy Forum is a twice-a-month, peer-reviewed, digital publication on current food and drug policy topics. Posed in the form of a question, each issue provides subscribers and purchasers with pertinent background information, relevant research, a discussion of central issues, relevant resources and policy recommendations. The views, opinions and statements expressed in the Policy Forum are those of the authors. The Food and Drug Law Institute neither contributes to nor endorses Policy Forum articles. As a nonprofit 501 (c) (3) organization, FDLI does not engage in advocacy activities.

FDLI, founded in 1949, is a non-profit organization that provides a marketplace for discussing food and drug law issues through conferences, publications and member interaction. FDLI's scope includes food, drugs, animal drugs, biologics, cosmetics, diagnostics, dietary supplements, medical devices and tobacco.

FDLI members receive the Policy Forum as a benefit of their membership. Non-members may subscribe to the Forum for a fee.


'/>"/>
SOURCE Food and Drug Law Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Change in Medicare Wheelchair Policy May Prevent Texas Beneficiaries from Receiving Mobility Assistance Starting January
2. Rural Wheelchair Patients Will Be Hit Hard by Power Wheelchair Rental Policy; Providers, Advocates Ask Congress for a Delay
3. K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSEs Shareholder Approval Policy
4. Congress Urged to Delay New Medicare Wheelchair Rental Policy
5. Medicare Policy Changes Will Make it More Difficult for Nevada Beneficiaries to Obtain Power Wheelchairs
6. Utahs Seniors and People with Disabilities Will Feel Impact of Medicare Policy Changes that Restrict Access to Power Wheelchairs
7. American College of Surgeons Health Policy Research Institute Releases Surgery Workforce Atlas That Shows Surgeon Shortage Across the U.S.
8. Physician Outraged by Medicare Power Wheelchair Documentation Policy
9. NORD Calls for Statement of Policy on Orphan Drug Development
10. Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities
11. Stryker Modifies Its Dividend Policy and Declares Transition Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
(Date:5/24/2017)... 2017  ivWatch LLC today announced the launch ... to enable seamless integration of ivWatch,s groundbreaking IV ... pumps and other devices. By integrating ivWatch technology ... help health care customers deliver a higher level ... IV therapy. "The ivWatch OEM Board ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... on the Peace Agreements being discussed by President Donald Trump and the rest of ... try to speed up peace talks in the continuous battle between Israel and Palestine. ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Dr. Alex Rabinovich, ... to announce a new, informational blog post on insurance options. If a Bay Area ... plans may help save time and money. Visiting an in-network provider for a second ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky Restoration ... from its 14th Annual Clays for Kids fundraiser, to be held Friday, Sept. ... , As part of BluSky’s partnership with The Adoption Exchange, BluSky will ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee ... a number of critical issues to address before students could return to classes. , ... or no disruption to class schedules. Second, the project had to comply with New ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is ... York City. He is known for his distinguished expertise and experience in the diagnosis ... holds sub-specialty training in treating renovascular disease and aortic aneurysm . He is ...
Breaking Medicine News(10 mins):